Showing results (1-10 of 5) with videos related to
Sort By:
Pageof 1
Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica|July 1, 2026
[Pharmacological properties and clinical trial results of datopotamab deruxtecan (Dato-DXd, Datroway<sup>®</sup>)]Takahiro Iijima, Daisuke OkajimaJournal of Receptor and Signal Transduction Research|April 7, 2010
Brain-specific angiogenesis inhibitor 2 (BAI2) may be activated by proteolytic processingDaisuke Okajima, Gen Kudo, Hiroshi YokotaThe Journal of Physiological Sciences : JPS|November 27, 2010
Antidepressant-like behavior in brain-specific angiogenesis inhibitor 2-deficient miceDaisuke Okajima, Gen Kudo, Hiroshi YokotaClinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 25, 2024
Antitumor Activity and Biomarker Analysis for TROP2 Antibody-Drug Conjugate Datopotamab Deruxtecan in Patient-Derived Breast Cancer Xenograft ModelsFunda Meric-Bernstam, Erkan Yuca, Kurt W Evans, et al.Molecular Cancer Therapeutics|August 20, 2021
Datopotamab Deruxtecan, a Novel TROP2-directed Antibody-drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor CellsDaisuke Okajima, Satoru Yasuda, Takanori Maejima, et al.Pageof 1